Page last updated: 2024-12-07

Molybdenum Mo-99

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Molybdenum-99 (Mo-99) is a radioactive isotope of molybdenum. It is a key component in the production of technetium-99m (Tc-99m), a widely used medical radioisotope for diagnostic imaging. Mo-99 is produced by bombarding uranium-235 with neutrons in a nuclear reactor. The resulting fission products include Mo-99, which is then extracted and purified. Mo-99 decays by beta emission, with a half-life of 66 hours, into Tc-99m. Tc-99m is then used to create radiopharmaceuticals for a wide range of medical imaging applications, such as bone scans, heart scans, and lung scans. The importance of Mo-99 stems from its role in producing Tc-99m, which is essential for modern medical diagnostics. Its study is driven by the need to ensure a reliable and sustainable supply of Tc-99m for medical use. Research focuses on improving the production and separation of Mo-99, developing alternative methods for producing Tc-99m, and exploring new applications for Mo-99 itself. '

Cross-References

ID SourceID
PubMed CID104976
CHEBI ID135936

Synonyms (22)

Synonym
14119-15-4
molybdenum mo-99
CHEBI:135936
molybdenum, isotope of mass 99
molybdenum-99
mo-99
unii-6634o61goi
99mo radioisotope
mo-99 radioisotope
technelite
99mo
6634o61goi ,
molybdenum,mo-99
molybdenum (99-mo)
mo 99
99 molybdenum
molybdenum, mo-99
molybdenum,mo-99 [vandf]
DTXSID70931019
(~99~mo)molybdenum
Q2341055
molybdenum99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
transition element molecular entityA molecular entity containing one or more atoms of a transition element.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (45.45)24.3611
2020's6 (54.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.25 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index89.36 (26.88)
Search Engine Supply Index2.70 (0.95)

This Compound (46.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]